HIM
KDNY

Hillsdale Investment Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Hillsdale Investment Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-39,086
Closed -$451K – 674
2020
Q2 		$451K Buy
+39,086
New +$539K 0.04% 345

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Hillsdale Investment Management's KDNY Position: Q3 2020 in Review

Hillsdale Investment Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2020, closing a stake of 39,086 shares — an estimated $451K sold.

Hillsdale Investment Management first reported a position in KDNY in Q2 2020 and held it in 1 quarter. The position peaked at $451K in Q2 2020. 70 funds tracked by Wall St. Rank hold KDNY as of Q3 2020.

  • Hillsdale Investment Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Hillsdale Investment Management sold 39,086 Chinook Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $451K.
  • Hillsdale Investment Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Hillsdale Investment Management's Chinook Therapeutics, Inc. Common Stock position peaked at $451K in Q2 2020.
  • 70 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Hillsdale Investment Management's 13F filing for Q3 2020, filed 13 Nov 2020.